Velishchuk
- Sonnet BioTherapeutics, (NASDAQ:SONN) entered into a $888M business combination with Rorschach I LLC, a newly formed entity by an entity affiliated with Atlas Merchant Capital, an affiliate of Paradigm Operations, and additional sponsors, to transform its business by building a reserve